These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 37537597)

  • 1. Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting.
    Zhao J; Ren Q; Liu X; Guo X; Song Y
    J Hematol Oncol; 2023 Aug; 16(1):92. PubMed ID: 37537597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma.
    Granger K; Gaffney KJ; Davis JA
    J Oncol Pharm Pract; 2023 Apr; 29(3):722-726. PubMed ID: 36775940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast.
    Landgren O; Nadeem O
    Adv Ther; 2023 Aug; 40(8):3291-3303. PubMed ID: 37328635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms.
    Lee H; Neri P; Bahlis NJ
    Blood; 2024 Mar; 143(13):1211-1217. PubMed ID: 38194680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting GPRC5D in multiple myeloma.
    Elemian S; Al Hadidi S
    Expert Rev Anticancer Ther; 2024 May; 24(5):229-238. PubMed ID: 38607646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bispecific antibodies as monotherapy or in combinations for hematological malignancies: latest updates from the EHA 2023 annual meeting.
    Li X; Zhang P; Sun H; Han L; Jiang Z; Yu J
    Expert Opin Biol Ther; 2023; 23(12):1193-1195. PubMed ID: 37852928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma.
    Pan D; Richter J
    Curr Hematol Malig Rep; 2024 Aug; ():. PubMed ID: 39145912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting.
    Xia J; Li Z; Xu K
    J Hematol Oncol; 2023 Jun; 16(1):60. PubMed ID: 37277826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Bispecific antibodies in multiple myeloma].
    Escure G; Manier S
    Bull Cancer; 2021 Oct; 108(10S):S205-S212. PubMed ID: 34920804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting.
    Hou J; Li Y; Lin Q
    Exp Hematol Oncol; 2023 Aug; 12(1):74. PubMed ID: 37633955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elranatamab vs. teclistamab: battle of the BCMA bispecifics in relapsed/refractory multiple myeloma.
    Moore DC; Granger K; Hill H; Karabinos A; Davis JA
    Expert Rev Hematol; 2024 Jun; 17(6):197-200. PubMed ID: 38717927
    [No Abstract]   [Full Text] [Related]  

  • 12. T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma.
    Verkleij CPM; Frerichs KA; Broekmans M; Absalah S; Maas-Bosman PWC; Kruyswijk S; Nijhof IS; Mutis T; Zweegman S; van de Donk NWCJ
    Oncotarget; 2020 Nov; 11(45):4076-4081. PubMed ID: 33227097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA.
    van de Donk NWCJ; O'Neill C; de Ruijter MEM; Verkleij CPM; Zweegman S
    Curr Opin Oncol; 2023 Nov; 35(6):601-611. PubMed ID: 37501530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma.
    Hammons L; Szabo A; Janardan A; Bhatlapenumarthi V; Annyapu E; Dhakal B; Al Hadidi S; Radhakrishnan SV; Narra R; Bhutani D; Thanendrarajan S; Janz S; Zangari M; Lentzsch S; Van Rhee F; Crescencio JCR; D'Souza A; Chakraborty R; Mohan M; Schinke C
    Haematologica; 2024 Mar; 109(3):906-914. PubMed ID: 37646658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The emerging therapeutic landscape of relapsed/refractory multiple myeloma.
    Tanenbaum B; Miett T; Patel SA
    Ann Hematol; 2023 Jan; 102(1):1-11. PubMed ID: 36462062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2021.
    Demel I; Bago JR; Hajek R; Jelinek T
    Br J Haematol; 2021 May; 193(4):705-722. PubMed ID: 33216972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrating Immune Therapies for the Treatment of Multiple Myeloma.
    Mikkilineni L; Sidana S
    J Natl Compr Canc Netw; 2023 Dec; 21(12):1303-1311. PubMed ID: 38081142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma.
    Davis JA; Shockley A; Hashmi H
    J Oncol Pharm Pract; 2022 Jun; 28(4):960-968. PubMed ID: 35006032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of bispecific antibodies therapy for relapsed or refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials.
    Wang X; Zhao A; Zhu J; Niu T
    Front Immunol; 2024; 15():1348955. PubMed ID: 38482019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.